Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Connect Biopharma Holdings Limited Ordinary Shares

CNTB

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Last trade $0.6101
Day change -$0.0329 (-5.12%)
Day range $0.551 – $0.633
Volume 753,303
Market cap $40M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$40.3M
Price / earnings
—
Price / book
1.5×
Price / sales
13.65×
EV / sales
4.5×
EV / EBITDA
-0.19×

Profitability

Earnings per share
-$1.10
Return on assets
-159.37%
Return on equity
-257.93%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
2.37×
Quick ratio
2.37×
Cash ratio
1.66×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$60.63M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CNTB, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$2.77M$169K$0$16K$48K$0$698K$1.22M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$2.77M$169K$0$16K$48K$0$698K$1.22M
Selling, general and administrative$4.1M$4.75M$4.24M$6.58M$4.7M$4.81M$4.08M$6.06M
Research and development$16.27M$15.03M$11.28M$11.11M$8.77M$6.63M$6.24M$9.01M
Total operating expenses$20.37M$19.78M$15.53M$17.69M$13.47M$11.45M$10.32M$15.07M
Operating income-$17.6M-$19.61M-$15.53M-$17.68M-$13.42M-$11.45M-$9.62M-$13.85M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$17.22M-$19.35M-$15.08M-$17.14M-$12.84M-$10.22M-$8.8M-$12.82M
Income taxes$60K$48K$27K$61K$55K$54K$106K$57K
Net income-$17.28M-$19.4M-$15.11M-$17.2M-$12.9M-$10.27M-$8.91M-$12.88M
Net income attributable to common shareholders-$17.28M-$19.4M-$15.5M-$17.1M-$12.9M-$10.27M-$9.33M-$12.31M
EBITDA-$17.44M-$19.44M-$15.35M-$17.5M-$13.25M-$11.27M-$9.46M-$13.67M
Basic earnings per share-$0.27-$0.34-$0.28-$0.31-$0.23-$0.19-$0.17-$0.23
Diluted earnings per share-$0.27-$0.34-$0.28-$0.31-$0.23-$0.19-$0.17-$0.23

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher

Connect Biopharma Holdings (CNTB) stock has declined 29.2% over the past four weeks but formed a hammer chart pattern in its last trading session, suggesting potential support and trend reversal. Rising analyst optimism about future earnings and a Zacks Rank #2 (Buy) rating support the possibility of a turnaround.

GlobeNewswire Inc.

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma reported Q1 2026 financial results and provided updates on its Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD. The independent Data Monitoring Committee confirmed no safety concerns and adequate study power, with topline data expected mid-2026. The company closed a $20.2 million private placement and has $46 million in cash, sufficient to fund operations into H2 2027. Positive Phase 1 IV rademikibart data showed rapid lung function improvements within 15 minutes.

The Motley Fool

Connect Biopharma Posts Q2 Revenue Drop

Connect Biopharma reported a significant revenue drop from $24.1 million to $48,000 in Q2 2025, increased R&D expenses, and a net loss of $12.9 million. The company continues developing rademikibart for inflammatory diseases and is progressing clinical trials.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.